alexa The VCORK1 Alleles Involved In The Pharmacogenetics Of Warfarin Anticoagulant Among Emiratis
ISSN: 1747-0862

Journal of Molecular and Genetic Medicine
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd International Conference on Genomics & Pharmacogenomics
September 08-10, 2014 DoubleTree by Hilton Hotel Raleigh-Brownstone-University, USA

Hayat Aljabeiji, Nadia A Akawi, Lihadh Al-Gazali and Bassam R Ali
Accepted Abstracts: J Mol Genet Med
DOI: 10.4172/1747-0862.S1.004
Introduction: Warfarin is one of the most prescribed anticoagulant drugs used in the prevention and treatment of thromboembolic vascular diseases. However, warfarin has a low therapeutic index and therefore has high risk of side effects and/ or therapeutic failure. Individual variation in drug response depends on variation in patient weight, height, gender, use of other anticoagulant drugs, co-medications, diet, patient compliance, and most importantly genetic variation. Recently, more studies are focusing on determining the initial warfarin dosing based on the genetic profile of these patients rather than a trial and error based dosing. Warfarin targets the vitamin K epoxide reductase VKORC1 and blocks its activity and therefore any functional mutations in the gene encoding this enzyme will perturb the balance between the influence of warfarin and vitamin K on the enzyme activity. The purpose of this study is to determine the alleles and genotypes and their frequencies among UAE nationals. Methods: Blood samples from Emirati subjects were collected and the promoter and allexonic and intronic regions were amplified by PCR and sequenced using Sanger Sequencing. Results: The alleles harboring the ?promoter region variant (-1639G >A,rs9923231) have been observed in a large proportion of the population. Other variants includingrs7294, rs9934438 and rs2884737 have also been observed. Conclusion: In Emirati population the promoter variant−1639G >A is common. The A allele is associated with the need of lower doses than the G allele. Homozygous carriers of the A allele require a warfarin dose approximately 50% of that of an individual that is homozygous for the G allele.
Hayat Aljabeiji is a pharmacist graduate from Dubai Pharmacy College and holds MBA from Griggs University. She is a pharmacogenomic researcher/ candidate for master program at UAE University. Prior to that, she worked as program manager at Institute of HealthCare Research at Cambridge Academy for Higher Education where she worked on a number of pharmaceutical and healthcare projects. Before that, she worked at Boots, Bin Sina Pharmacies as a pharmacist and at AXA Insurance as a Medical Advisor.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version